grant
Nanoreactor beads for POC TB resistance testing
Organization RUTGERS BIOMEDICAL AND HEALTH SCIENCESLocation Newark, UNITED STATESPosted 7 Nov 2023Deadline 31 Oct 2028
NIHUS FederalResearch GrantFY2025AddressAntitubercular DrugsAssayBenemycinBioassayBiological AssayBlinkingCatalogsChemistryClinicalCollaborationsCompanionsDNA mutationDetectionDevelopmentDevicesDiagnosticDiagnostic testsDiseaseDisorderDrug Resistance TuberculosisDrug Resistant TBDrug Resistant TuberculosisDrug resistanceDrug resistance in MtbDrug resistance in Mycobacterium TuberculosisDrug resistance in tuberculosisDrug resistant M TuberculosisDrug resistant MtbDrug resistant Mycobacteria TuberculosisDrugsEngineeringEthambutolFluoroquinolonesFoundationsFutureGenesGenetic ChangeGenetic defectGenetic mutationHeteroresistanceHeteroresistantIntermediate resistanceIntermediate resistantIsonicotinic Acid HydrazideLMICLaboratoriesLengthLinezolidM . tuberculosis resistanceM tbM tuberculosisM tuberculosis infectionM. tbM. tb infectionM. tuberculosisM. tuberculosis infectionM.tb infectionM.tuberculosis infectionMTB infectionMechanicsMedicationMolecularMtb drug resistanceMtb resistanceMutationMutation DetectionMycobacterium tuberculosisMycobacterium tuberculosis (MTB) infectionMycobacterium tuberculosis infectionMycobacterium tuberculosis resistanceNational Institutes of HealthNucleic Acid Amplification TechnicsNucleic Acid Amplification TechniquesNucleic AcidsPZA resistancePZA resistantPerformancePharmaceutical PreparationsPredispositionProcessPyrazinamidePyrazinamide resistancePyrazinamide resistantPyrazinecarboxamideRapid diagnosticsResearch ResourcesResearch SpecimenResistanceResistance to PZAResistance to PyrazinamideResistant to PZAResistant to PyrazinamideResourcesRifadinRifampicinRifampinRimactaneRiskSamplingScientistSpecificitySpecimenSpinal ColumnSpineSputumSusceptibilitySystemTB diagnosticsTB drug resistanceTB drugsTB infectionTB resistanceTB therapyTB treatmentTechnologyTemperatureTestingTimeTuberculosisUnited States National Institutes of HealthVertebral columnZyvoxanalytical methodanti-TB drugsanti-tuberculosis drugsbackbonecatalogcausal allelecausal genecausal mutationcausal variantcausative mutationcausative variantclinical relevanceclinical validationclinically relevantdesigndesigningdetection limitdetection platformdetection systemdevelopmentaldiagnostic developmentdigitaldisseminated TBdisseminated tuberculosisdrug resistance M Tuberculosisdrug resistance Mycobacteria Tuberculosisdrug resistance in TBdrug resistantdrug resistant M.tbdrug resistant in tuberculosisdrug/agenteye blinkeyeblinkfluoroquinolone resistancefluoroquinolone resistantgenome mutationinfection due to Mycobacterium tuberculosisinnovateinnovationinnovativeinstrumentisoniazidlow and middle-income countriesmechanicmechanicalmeltingmolecular diagnosticsmtbmutantnanonew diagnosticsnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation diagnosticsnext generation therapeuticsnovelnovel diagnosticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypoint of carepoint of care testingpromoterpromotorrapid diagnosisresistance generesistance in M . tuberculosisresistance in Mycobacterium tuberculosisresistance in TBresistance in tuberculosisresistance locusresistance mutationresistance to Drugresistance to fluoroquinoloneresistantresistant M . tuberculosisresistant Mtbresistant Mycobacterium tuberculosisresistant TBresistant generesistant mutationresistant to Drugresistant to fluoroquinoloneresistant tuberculosistreat M. tuberculosistreat Mtbtreat Mycobacterium tuberculosistreat tbtreat tuberculosistuberculosis diagnosticstuberculosis drugstuberculosis infectiontuberculosis resistancetuberculosis therapytuberculosis treatmenttuberculous spondyloarthropathyvalidation studies
Description preview
ABSTRACT
Rapid and sensitive point of care tests that can detect all forms of drug resistance in tuberculosis (TB) are
urgently needed to address the rise of drug resistance. We propose to develop a novel mutation detection system
that uses recently developed nanoreactor bead chemistry and the Blink Diagnostic’s testing platform to identify
both…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click